Liquid biopsy: paving a new avenue for cancer research.
Cell Adh Migr
; 18(1): 1-26, 2024 Dec.
Article
in En
| MEDLINE
| ID: mdl-39219215
ABSTRACT
The current constraints associated with cancer diagnosis and molecular profiling, which rely on invasive tissue biopsies or clinical imaging, have spurred the emergence of the liquid biopsy field. Liquid biopsy involves the extraction of circulating tumor cells (CTCs), circulating free or circulating tumor DNA (cfDNA or ctDNA), circulating cell-free RNA (cfRNA), extracellular vesicles (EVs), and tumor-educated platelets (TEPs) from bodily fluid samples. Subsequently, these components undergo molecular characterization to identify biomarkers that are critical for early cancer detection, prognosis, therapeutic assessment, and post-treatment monitoring. These innovative biosources exhibit characteristics analogous to those of the primary tumor from which they originate or interact. This review comprehensively explores the diverse technologies and methodologies employed for processing these biosources, along with their principal clinical applications.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biomarkers, Tumor
/
Neoplastic Cells, Circulating
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Cell Adh Migr
Year:
2024
Document type:
Article
Affiliation country:
Francia
Country of publication:
Estados Unidos